TobaccoReporter logo

Tag: Mark Tyndall

  • ATNF Talks Challenges in Communicating Tobacco Harm Reduction

    ATNF Talks Challenges in Communicating Tobacco Harm Reduction

    At the American Tobacco and Nicotine Forum (ATNF), a panel titled “Tobacco Harm Reduction: Communicating to Adults Who Smoke” brought together public health experts, physicians, and industry representatives to examine why reduced-risk messaging is failing to reach adult smokers. Moderated by Cliff Douglas, president of Tobacco Control Law and Policy Consulting, the discussion focused on the disconnect between scientific evidence, regulatory communication, and real-world consumer understanding, with panelists pointing to a significant opportunity to better engage healthcare providers as trusted intermediaries. Douglas said the number of contrasting views from “authorities” in government and industries has eroded trust of consumers across most markets.

    Dr. Mohamadi Sarkar, a fellow in regulatory affairs for Altria Client Services, emphasized the scale of misinformation, noting that many smokers believe vaping is as harmful as smoking and that nicotine pouches cause cancer—perceptions he said are not supported by current evidence. He argued that while regulators acknowledge a continuum of risk, that message is not reaching consumers due to communication restrictions and slow dissemination of scientific findings. Sarkar also highlighted that even physicians often lack awareness of tobacco regulation and product differences, suggesting that a grassroots, evidence-based approach—combined with better education of healthcare providers—could gradually shift understanding and influence patient decisions.

    Dr. Mark Tyndall, an author and vaping advocate, framed harm reduction through a clinical lens, arguing that abstinence-only messaging is ineffective and that switching to lower-risk products should be treated as a pragmatic health intervention. He compared nicotine alternatives to substitution therapies in other areas of medicine, stressing that providing safer options is both ethical and necessary. Dr. Julie Gunther, a physician based in Boise, Idaho, reinforced the practical challenges physicians face, noting limited patient interaction time and a lack of nuanced education within the medical system. She said most healthcare environments do not differentiate between nicotine products, while real influence increasingly comes from peers, pharmacists, and social media. Across the panel, speakers pointed to stigma, regulatory constraints, and inconsistent public health messaging as key barriers, with calls for clearer, fact-based communication to help adult smokers make more informed choices.

  • ATNF Explores Shifting Dialogue in Tobacco Harm Reduction

    ATNF Explores Shifting Dialogue in Tobacco Harm Reduction

    At the American Tobacco and Nicotine Forum (ATNF), the panel titled “From ‘You Can’t Be Here’ to ‘We Need to Talk’” focused on the evolving relationship between public health advocates and the tobacco and nicotine industry, highlighting a gradual shift from outright exclusion toward cautious engagement. Moderated by Joe Gitchell, the CEO of PinneyAssociates, the discussion centered on the importance of dialogue across opposing viewpoints, with panelists reflecting on how entrenched positions, mistrust, and policy rigidity have slowed progress in reducing smoking-related harm.

    A recurring theme was how perspectives have changed over time. Dave Dobbins, the Principal Consultant of Dobbins Consulting, described moving from skepticism about e-cigarettes—once believed to be a gateway to smoking—to recognizing their potential role in harm reduction, while also criticizing high taxes and prohibition-style policies for slowing progress. Dr. Jonathan Foulds, a professor of Public Health at Penn State University, acknowledged misjudging both the appeal of alternative nicotine products and the industry’s ability to transition away from cigarettes, arguing that regulatory barriers and misinformation have hindered adoption of less harmful options. He emphasized the need to focus on current smokers—particularly older populations who face near-term health risks—while avoiding strategies that could drive youth uptake. Dr. Mark Tyndall, an author and vaping advocate, reinforced harm reduction principles drawn from his experience in HIV prevention, arguing that safer alternatives should be embraced more pragmatically, even as resistance persists within parts of the public health community.

    Panelists also examined the structural and philosophical divides shaping policy. Phil Wilbur, a retired public health expert, representing a traditional tobacco control perspective, stressed that reducing disease and death remains the central goal, while acknowledging past missteps, including an overemphasis on youth prevention strategies that did not fully succeed. The discussion highlighted ongoing tensions around prohibition versus harm reduction, with broad agreement that outright bans are ineffective and risk fueling illicit markets. At the same time, speakers pointed to deep-rooted mistrust of the tobacco industry as a barrier to collaboration, with suggestions ranging from clearer risk communication to restructuring incentives so companies benefit from transitioning away from combustible products. Across the panel, there was consensus that meaningful progress will require more open, evidence-based dialogue—moving beyond binary “good versus evil” narratives toward practical solutions that reflect real-world behavior and market dynamics.